Allenex to launch new HLA typing technology in 2015

During 2014, Allenex has started the development of brand new HLA typing tests
based on the method of real-time PCR. The aim is to launch the products during
the second quarter of 2015. The advantage of the real-time PCR method is that it
is simpler and faster compared to currently used HLA typing methods.

"We see great value in being able to offer Allenex customers worldwide HLA
typing products based on the method of real-time PCR" says Allenex CEO Anders
Karlsson, and he continues: "HLA typing based on the method of real-time PCR is
more rapid and efficient. It is especially valuable for on-call deceased donor
typing for solid organ transplantation. In these situations you need the testing
done quickly and often outside of regular working hours, which place a high
demand on simplicity and automation. We regard our upcoming new real-time PCR
HLA typing product as a natural extension of our existing product line.” he
concludes.

Real-time PCR is already used today in many laboratories for other types of
diagnosis, e.g. for cancer and infection diagnostics. It is, however, an
underutilized analytical method for HLA typing, where Allenex currently is a
world leader with the Olerup SSP products. The development project will run
mainly internally at Allenex subsidiary Olerup SSP AB. These new products will
be offered as an addition to the current products. As of today there is one
competing product for this segment, but Allenex expects the usage to increase
significantly in the years ahead. Allenex now sees an opportunity to attract new
customers for our whole HLA typing product range. Today, Allenex presents this
project at a conference in Denver, Colorado organized by ASHI (American Society
for Histocompatibility and Immunogenics)
SSP technology for transplantation matching, HLA typing, is the technology used
today at most HLA typing laboratories in the world. Globally, more than 100,000
organ transplants are done annually and a low resolution HLA typing is a
prerequisite, so that compatibility between donor and recipient can be
guaranteed.

This first real-time PCR HLA typing product introduced by Allenex will target
the low to intermediate resolution HLA typing needs for organ transplantation.

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on October 21, 2014, at 08.45 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the
Allenex group.